Detalles de la búsqueda
1.
Protocol for the nationwide registry of patients with polycystic kidney disease: japanese national registry of PKD (JRP).
Clin Exp Nephrol
; 2024 May 11.
Artículo
en Inglés
| MEDLINE | ID: mdl-38734869
2.
Long-Term Effects of Tolvaptan in Autosomal Dominant Polycystic Kidney Disease: Predictors of Treatment Response and Safety over 6 Years of Continuous Therapy.
Int J Mol Sci
; 25(4)2024 Feb 08.
Artículo
en Inglés
| MEDLINE | ID: mdl-38396765
3.
Public support for patients with intractable diseases in Japan: impact on clinical indicators from nationwide registries in patients with autosomal dominant polycystic kidney disease.
Clin Exp Nephrol
; 27(10): 809-818, 2023 Oct.
Artículo
en Inglés
| MEDLINE | ID: mdl-37368094
4.
Chapter 1: Evaluation of kidney function in patients undergoing anticancer drug therapy, from clinical practice guidelines for the management of kidney injury during anticancer drug therapy 2022.
Int J Clin Oncol
; 28(10): 1259-1297, 2023 Oct.
Artículo
en Inglés
| MEDLINE | ID: mdl-37382749
5.
Clinical Practice Guidelines for tuberous sclerosis complex-associated renal angiomyolipoma by the Japanese Urological Association: Summary of the update.
Int J Urol
; 30(10): 808-817, 2023 10.
Artículo
en Inglés
| MEDLINE | ID: mdl-37278492
6.
Preservation of kidney function irrelevant of total kidney volume growth rate with tolvaptan treatment in patients with autosomal dominant polycystic kidney disease.
Clin Exp Nephrol
; 25(5): 467-478, 2021 May.
Artículo
en Inglés
| MEDLINE | ID: mdl-33471240
7.
Imaging Identification of Rapidly Progressing Autosomal Dominant Polycystic Kidney Disease: Simple Eligibility Criterion for Tolvaptan.
Am J Nephrol
; 51(11): 881-890, 2020.
Artículo
en Inglés
| MEDLINE | ID: mdl-33227802
8.
Correction to: Public support for patients with intractable diseases in Japan: impact on clinical indicators from nationwide registries in patients with autosomal dominant polycystic kidney disease.
Clin Exp Nephrol
; 28(1): 82-83, 2024 Jan.
Artículo
en Inglés
| MEDLINE | ID: mdl-37924433
9.
Novel semi-automated kidney volume measurements in autosomal dominant polycystic kidney disease.
Clin Exp Nephrol
; 22(3): 583-590, 2018 Jun.
Artículo
en Inglés
| MEDLINE | ID: mdl-29101551
10.
A potentially crucial role of the PKD1 C-terminal tail in renal prognosis.
Clin Exp Nephrol
; 22(2): 395-404, 2018 Apr.
Artículo
en Inglés
| MEDLINE | ID: mdl-28983800
11.
A digest from evidence-based Clinical Practice Guideline for Polycystic Kidney Disease 2020.
Clin Exp Nephrol
; 25(12): 1292-1302, 2021 Dec.
Artículo
en Inglés
| MEDLINE | ID: mdl-34564792
12.
Association of arginine vasopressin surrogate marker urinary copeptin with severity of autosomal dominant polycystic kidney disease (ADPKD).
Clin Exp Nephrol
; 19(6): 1199-205, 2015 Dec.
Artículo
en Inglés
| MEDLINE | ID: mdl-25715868
13.
Exploring urinary biomarkers in autosomal dominant polycystic kidney disease.
Clin Exp Nephrol
; 19(5): 968-73, 2015 Oct.
Artículo
en Inglés
| MEDLINE | ID: mdl-25543187
14.
The effect of tolvaptan on autosomal dominant polycystic kidney disease patients: a subgroup analysis of the Japanese patient subset from TEMPO 3:4 trial.
Clin Exp Nephrol
; 19(5): 867-77, 2015 Oct.
Artículo
en Inglés
| MEDLINE | ID: mdl-25663351
15.
High prevalence of frailty in patients with lower urinary tract symptoms.
Geriatr Gerontol Int
; 23(8): 609-615, 2023 Aug.
Artículo
en Inglés
| MEDLINE | ID: mdl-37528501
16.
Retrospective observational study of a novel smartphone app on the management of patients with mild cognitive impairment or mild dementia.
Front Digit Health
; 5: 1243253, 2023.
Artículo
en Inglés
| MEDLINE | ID: mdl-37767524
17.
PKD1 Mutation Is a Biomarker for Autosomal Dominant Polycystic Kidney Disease.
Biomolecules
; 13(7)2023 06 21.
Artículo
en Inglés
| MEDLINE | ID: mdl-37509056
18.
Gut environment changes due to androgen deprivation therapy in patients with prostate cancer.
Prostate Cancer Prostatic Dis
; 26(2): 323-330, 2023 06.
Artículo
en Inglés
| MEDLINE | ID: mdl-35418210
19.
Bone scan index (BSI) scoring by using bone scintigraphy and circulating tumor cells (CTCs): predictive factors for enzalutamide effectiveness in patients with castration-resistant prostate cancer and bone metastases.
Sci Rep
; 13(1): 8704, 2023 05 29.
Artículo
en Inglés
| MEDLINE | ID: mdl-37248346
20.
Urine spermine and multiparametric magnetic resonance imaging for prediction of prostate cancer in Japanese men.
Prostate Int
; 11(3): 180-185, 2023 Sep.
Artículo
en Inglés
| MEDLINE | ID: mdl-37745906